Bringing viral production to the next level
The scale-X™ bioreactor portfolio provides enhanced upstream processing of viral products. Featuring a structured and intensified fixed-bed design, scale-X™ bioreactors are chained with in-line product concentration. It offers a linear scalability from the bench to the plant (R&D to commercial), perfectly suited to deliver your viral vaccines and gene therapies.
Portfolio
Scalability from discovery to commercial manufacturing
The scale-X™ technology was designed to achieve cost-effective large capacity production. Integrated into the NevoLine™ Upstream platform, the scale-X™ nitro bioreactor enables the future of large-scale viral production.
The scale-X™ hydro and carbo systems offer scale-down models suited to meet smaller production demands.
Scale-X carbo
scale-X™ carbo bioreactor system
Bench-scale automated cell culture system for expression and concentration of viral drug substance, featuring a single-use bioreactor offering 10 to 30 m² growth surface.
The scale-X™ carbo system is suited for rapid process development and cost-effective clinical production.
Click & Learn
Reinventing benchtop production
Benefits
Scalability
Structured fixed-bed design ensures predictable behavior for seamless scale-up throughout the scale-X range.
Reliability
Homogeneous cell distribution delivers reproducible performance coupled with cell sampling for direct monitoring.
Cost-effectiveness
Low footprint, integrated system produces high cell densities and viral titers to ize capital investment and reduce operating costs.
Downloads
Related Publications
scale-X™ carbo bioreactor system for rapid process development
The scale-X™ carbo system is a bench-scale automated cell culture system for expression and concentration of viral drug substance, suited for rapid process development and cost-effective clinical production.
DownloadPromising Vero cell growth in scale-X™ bioreactors
Case study comparing adherent Vero cell growth on microcarriers and intensified, fixed-bed scale-X bioreactors hydro (2.4 m²) and carbo (10-30 m²). Results demonstrate the scale-X bioreactors as a suitable alternative to traditional technologies.
Learn moreHow one CDMO used innovative technology to overcome viral vaccine production challenges?
Discover how Ology Biosciences is leveraging Univercells Technologies’ intensified fixed-bed bioreactor and bioprocessing expertise to bring vaccine production to the next level. Get case study results and expert insights on how to find success with adherent-cell growth profiles and viral performance to produce viral vaccines using the scale-X bioreactors.
Visit siteServices & maintenance
Shortcut to your success
Our experienced Application and Service Engineering teams are available to support the installation and qualification of your equipment, provide basic and advanced process training, and ensure maintenance throughout the lifetime of your system.
Choose the service offering suited to your needs and rely on our dedicated teams to further support your operations.